Subvolts take Zuckerberg and Chan detail their AI-driven approach to revolutionizing biology and medicine. Feb 1, 2026
For you
Developers
Learn how AI is being applied to complex scientific problems, potentially opening new avenues for research tools.
Business
Understand how major initiatives are investing in AI for long-term scientific and medical advancements.
Hype note
3/5Notable

This interview features key figures discussing significant long-term investments in AI for biological research and medicine.

The AI-Powered Biohub: Why Mark Zuckerberg & Priscilla Chan are Investing in Data, from Latent.Space

1 h 02 Interview Hosts: Nathan Labenz
0:001:02:12

Audio streams from Erik Torenberg, Nathan Labenz. Your place is remembered on this device.

From Subvolts

Summary and analysis by Subvolts editorial, AI-assisted.

Summary

Mark Zuckerberg and Priscilla Chan discuss the Chan Zuckerberg Initiative's expanded Biohub vision on its 10th anniversary. They explore how a "Frontier Biology Lab" and "Frontier AI Lab" working together can drive breakthroughs like a Virtual Cell and personalized medicine. The conversation covers acquiring Evolutionary Scale, collecting biological data at scale, and AI's role in transforming drug discovery and disease prevention.

Explained simply

Mark Zuckerberg and Priscilla Chan are investing heavily in AI to understand biology better. They believe AI can help create a "virtual cell" and develop treatments tailored to individuals, potentially transforming how we fight disease.

Why listen

This episode offers insight into Meta cofounder Mark Zuckerberg's long-term vision for AI in biology. Listeners learn how integrating AI with biological research aims to accelerate discoveries in medicine and disease. It is for anyone interested in the intersection of AI and life sciences, particularly how major labs like Meta AI are investing in fundamental research. This aligns with current frontier lab efforts to apply large models to scientific challenges beyond typical consumer applications.

On the mic
  • HostNathan Labenz
  • GuestMark ZuckerbergChan Zuckerberg Initiative
  • GuestPriscilla ChanChan Zuckerberg Initiative
About
Key facts
  • Episode Title: The AI-Powered Biohub: Why Mark Zuckerberg & Priscilla Chan are Investing in Data, from Latent.Space
  • Show: The Cognitive Revolution
  • Length: 62 minutes
  • Anniversary: 10-year anniversary of the Chan Zuckerberg Initiative
  • Acquisition: Acquisition of Evolutionary Scale and ESM3
Show notes from Erik Torenberg, Nathan Labenz

This crossover episode from the Latent Space podcast features Mark Zuckerberg and Priscilla Chan on the 10-year anniversary of the Chan Zuckerberg Initiative and their expanded Biohub vision. They discuss how a “Frontier Biology Lab” working in sync with a “Frontier AI Lab” could enable breakthroughs like a Virtual Cell and true N-of-1 precision medicine. The conversation covers the acquisition of Evolutionary Scale and ESM3, new biological data collection at scale, and how AI-powered biology might transform drug discovery and disease prevention.

Sponsors:

Blitzy:

Blitzy is the autonomous code generation platform that ingests millions of lines of code to accelerate enterprise software development by up to 5x with premium, spec-driven output. Schedule a strategy session with their AI solutions consultants at https://blitzy.com

Framer:

Framer is an enterprise-grade website builder that lets business teams design, launch, and optimize their.com with AI-powered wireframing, real-time collaboration, and built-in analytics. Start building for free and get 30% off a Framer Pro annual plan at https://framer.com/cognitive

Serval:

Serval uses AI-powered automations to cut IT help desk tickets by more than 50%, freeing your team from repetitive tasks like password resets and onboarding. Book your free pilot and guarantee 50% help desk automation by week four at https://serval.com/cognitive

Tasklet:

Tasklet is an AI agent that automates your work 24/7; just describe what you want in plain English and it gets the job done. Try it for free and use code COGREV for 50% off your first month at https://tasklet.ai

Claude

Claude is the AI collaborator that understands your entire workflow, from drafting and research to coding and complex problem-solving. Start tackling bigger problems with Claude and unlock Claude Pro’s full capabilities at ⁠⁠https://claude.ai/tcr⁠

CHAPTERS:

(00:00) About the Episode

(04:27) CZI origins and focus

(08:29) Why tools over cures

(14:43) Virtual cells and imaging (Part 1)

(20:19) Sponsors: Blitzy | Framer

(23:24) Virtual cells and imaging (Part 2)

(25:22) Data diversity and grounding

(32:30) Evaluating models and Biohub (Part 1)

(37:53) Sponsors: Serval | Tasklet

(40:42) Evaluating models and Biohub (Part 2)

(41:06) Future healthcare and aging

(53:39) Modeling scales and immunity

(58:53) Timelines, data, and collaboration

(01:04:01) Outro

PRODUCED BY:

https://aipodcast.ing

SOCIAL LINKS:

Website: https://www.cognitiverevolution.ai

Twitter (Podcast): https://x.com/cogrev_podcast

Twitter (Nathan): https://x.com/labenz

LinkedIn: https://linkedin.com/in/nathanlabenz/

Youtube:

N-of-1 precision medicine
Mark Zuckerberg and Priscilla Chan
Medical treatments designed specifically for one individual person based on their unique biology.
Virtual Cell
Mark Zuckerberg and Priscilla Chan
A computer simulation that models the behavior and functions of a real biological cell.
Published
Show
The Cognitive Revolution · Erik Torenberg, Nathan Labenz
Length
1 h 02
Companies
Meta
Products
ESM3
Summary by
Subvolts, using an AI model (how we work). Spotted a mistake? Tell us.

Same guests, other shows

Questions people ask

What is the Chan Zuckerberg Initiative's Biohub vision?
The Biohub vision involves a "Frontier Biology Lab" working with a "Frontier AI Lab" to enable breakthroughs like a Virtual Cell and N-of-1 precision medicine.
What AI-related acquisitions did they mention?
They discussed the acquisition of Evolutionary Scale and its ESM3 model.

Page generated Oct 19, 2026. Summaries are Subvolts' own; the audio, artwork and notes belong to Erik Torenberg, Nathan Labenz.